Ellingson Rachel 4

What Happened Rachel Ellingson, a director of BioLife Solutions, was granted 8,170 restricted shares (transaction code A) on 2026-02-24 under the BioLife Solutions 2023 Performance Incentive Plan. No purchase price or dollar value is reported in the filing because these are a compensation award rather than an open-market trade.

Key Details

• Transaction date: 2026-02-24; filing date (Accession): 2026-02-26 (filed within the typical 2-business-day Form 4 window).
• Shares granted: 8,170 restricted shares; price per share: N/A (award).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnote: The restricted stock was granted under the 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026" (i.e., fully vested on Jan 2, 2027).
• No 10b5-1 plan, cashless exercise, or tax-withholding details are noted in the excerpt.

Context Restricted stock awards are common executive/director compensation and generally reflect pay rather than an immediate market view. Because this is a grant (not a purchase or sale), it should be viewed as compensation-related disclosure; it does not by itself indicate the insider is buying or selling shares based on company outlook.